Related Experiment Video
Updated: Aug 8, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Breast cancer chemoprevention: beyond tamoxifen
1University of Kansas Medical Center, Kansas City, Kansas 66160-7320, USA. cfabian@kumc.edu
Abstract:
A large number of new potential chemoprevention agents are available that target molecular abnormalities found in estrogen receptor (ER)-negative and/or ER-positive precancerous breast tissue and have side effect profiles that differ from tamoxifen. Classes of agents currently undergoing evaluation in clinical prevention trials or those for which testing is planned in the near future include new selective ER modulators, aromatase inactivators/inhibitors, gonadotrophin-releasing hormone agonists, monoterpenes, isoflavones, retinoids, rexinoids, vitamin D derivatives, and inhibitors of tyrosine kinase, cyclooxygenase-2, and polyamine synthesis. New clinical testing models will use morphological and molecular biomarkers to select candidates at highest short-term risk, to predict the response to a particular class of agent, and to assess the response in phase II prevention trials. If validated, morphological and molecular markers could eventually replace cancer incidence as an indicator of efficacy in future phase III trials.
Insights
New breast cancer chemoprevention agents target molecular abnormalities and offer alternatives to tamoxifen. Biomarkers will refine patient selection and efficacy assessment in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Emerging chemoprevention agents target molecular abnormalities in estrogen receptor (ER)-negative and ER-positive precancerous breast tissue.
- These agents possess distinct side effect profiles compared to tamoxifen.
Purpose of the Study:
- To review novel chemoprevention agents and their potential in breast cancer prevention.
- To discuss the role of biomarkers in optimizing clinical trial design and efficacy assessment.
Main Methods:
- Review of current and planned clinical prevention trials for breast cancer.
- Analysis of emerging classes of chemoprevention agents, including selective ER modulators, aromatase inhibitors, and targeted therapies.
- Evaluation of biomarker strategies for patient selection and response assessment.
Main Results:
- A diverse array of chemoprevention agents are under investigation, including selective ER modulators, aromatase inactivators, gonadotrophin-releasing hormone agonists, monoterpenes, isoflavones, retinoids, rexinoids, vitamin D derivatives, and inhibitors of tyrosine kinase, cyclooxygenase-2, and polyamine synthesis.
- New clinical trial models will incorporate morphological and molecular biomarkers for risk stratification, treatment prediction, and efficacy evaluation.
Conclusions:
- Validated biomarkers could enhance the precision of breast cancer prevention trials, potentially replacing cancer incidence as a primary endpoint.
- Novel chemoprevention strategies offer promising alternatives with improved safety and efficacy profiles.
More Related Videos
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
Related Concept Videos
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Preventive Healthcare Services
Cancer Prevention
Some...
Treatment Resistent Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...